Please use this identifier to cite or link to this item:
|Title:||Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness.|
|Authors:||Burrows, Graham D;McIntyre, I M;Judd, F K;Norman, Trevor R|
|Affiliation:||Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.|
|Citation:||The Journal of Clinical Psychiatry; 49 Suppl(): 18-22|
|Abstract:||The serotonergic hypothesis of depression has stimulated the development of a range of chemically diverse compounds that have an exclusive effect on this neurotransmitter for potential use as antidepressant drugs. The group of serotonin reuptake inhibitors are at various stages of clinical development. The authors review the efficacy, side effect profiles, and toxicity of zimelidine, fluvoxamine, and citalopram in detail and ifoxetine, fluoxetine, indalpine, paroxetine, and sertraline in brief. Evidence suggests that, compared with tricyclic antidepressants, these drugs may cause fewer anticholinergic effects and lower cardiotoxicity in the treatment of major depressive disorders. These advantages need to be weighed against an emerging pattern of gastrointestinal complaints, insomnia, and akathisia. The place of serotonin reuptake inhibitors in therapy can be fully evaluated only after further studies, particularly those involving long-term use. The adverse experience associated with zimelidine suggests that caution and vigilance should be exercised in future studies of agents in this class. These drugs will undoubtedly provide important insights into depressive illness and some anxiety disorders and may fulfill their initial promise.|
|Internal ID Number:||3045107|
|Subjects:||Clinical Trials as Topic|
Depressive Disorder.drug therapy
Serotonin Antagonists.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.